NKG2D-Deficient Mice Are Defective in Tumor Surveillance in Models of Spontaneous Malignancy  by Guerra, Nadia et al.
Immunity
ArticleNKG2D-Deficient Mice Are Defective
in Tumor Surveillance in Models
of Spontaneous Malignancy
Nadia Guerra,1 Ying Xim Tan,1,5 Nathalie T. Joncker,1,5 Augustine Choy,1 Fermin Gallardo,1 Na Xiong,1 Susan Knoblaugh,3
Dragana Cado,2 Norman R. Greenberg,4 and David H. Raulet1,2,*
1Department of Molecular and Cell Biology
2Cancer Research Laboratory
489 Life Sciences Addition, University of California, Berkeley, Berkeley, CA 94720, USA
3Animal Health Shared Resource
4Clinical Research Division
Fred Hutchinson Cancer Research Center, 1100 Fairview Avenue N. D4-100, Seattle, WA 98109-1024, USA
5These authors contributed equally to this work.
*Correspondence: raulet@berkeley.edu
DOI 10.1016/j.immuni.2008.02.016SUMMARY
Ligands for the NKG2D stimulatory receptor are fre-
quently upregulated on tumor lines, rendering them
sensitive to natural killer (NK) cells, but the role of
NKG2D in tumor surveillance has not been ad-
dressed in spontaneous cancer models. Here, we
provided the first characterization of NKG2D-defi-
cient mice, including evidence that NKG2D was not
necessary for NK cell development but was critical
for immunosurveillance of epithelial and lymphoid
malignancies in two transgenic models of de novo
tumorigenesis. In both models, we detected NKG2D
ligands on the tumor cell surface ex vivo, providing
needed evidence for ligand expression by primary tu-
mors. In a prostate cancer model, aggressive tumors
arising in NKG2D-deficient mice expressed higher
amounts of NKG2D ligands than did similar tumors
in wild-type mice, suggesting an NKG2D-dependent
immunoediting of tumors in this model. These find-
ings provide important genetic evidence for surveil-
lance of primary tumors by an NK receptor.
INTRODUCTION
NKG2D is a stimulatory immunoreceptor expressed by natural
killer (NK) cells and various T cell subsets, including activated
CD8+ T cells, fractions of gamma-delta, NKT cells, and some ac-
tivated CD4+ T cells (Groh et al., 2001; Groh et al., 1999; Jamie-
son et al., 2002; Raulet, 2003; Saez-Borderias et al., 2006). The
receptor binds to several NKG2D ligands, including the MICA
and MICB (MHC class I chain related) proteins expressed by hu-
mans but not mice (Bauer et al., 1999), and a family of proteins
called Rae1 (mouse) or ULBP (human), shared by rodents and
humans [(Cerwenka et al., 2000; Cosman et al., 2001; Diefen-
bach et al., 2000), reviewed in (Raulet, 2003)].
NKG2D ligands are poorly expressed by normal cells but are
frequently upregulated in tumor cells (Groh et al., 1999), tumor
cell lines (Cerwenka et al., 2000; Diefenbach et al., 2000; Pendeet al., 2001; Pende et al., 2002), and in some infected cells
(Gourzi et al., 2006; Lodoen et al., 2003; Siren et al., 2004). The
mechanisms leading to ligand upregulation are under investiga-
tion (Cerwenka et al., 2000; Gasser et al., 2005; Hamerman et al.,
2005). One pathway that has been implicated is the DNA-dam-
age-response pathway (Gasser et al., 2005), which is frequently
activated in precancerous lesions as well as advanced tumors
(Bartkova et al., 2005; Gorgoulis et al., 2005). Ligand-expressing
cells can activate NKG2D-expressing NK cells or T cells in vitro
(Bauer et al., 1999; Cerwenka et al., 2000; Diefenbach et al.,
2000). Transfected tumor cell lines expressing NKG2D ligands
are rejected in vivo in an NKG2D-dependent fashion (Cerwenka
et al., 2001; Diefenbach et al., 2001). Whereas these findings are
consistent with a role of NKG2D in tumor surveillance, there is lit-
tle direct evidence for such a role. Indeed, at least some tumors
may evade NKG2D surveillance (Coudert et al., 2005; Groh et al.,
2002; Oppenheim et al., 2005). For instance, some cancers shed
high amounts of soluble NKG2D ligands, which are believed to
cause downregulation of NKG2D on the surface of lymphocytes
(Groh et al., 2002).
In addition to a potential role in tumor surveillance, NKG2D has
been implicated in pathogen immunity (Cosman et al., 2001;
Groh et al., 2001), autoimmunity (Groh et al., 2003; Ogasawara
et al., 2004), and graft rejection (Ogasawara et al., 2005). In order
to address the role of NKG2D (encoded byKlrk1) in vivo, we have
generated and characterized NKG2D-deficient mice. We
showed that NKG2D-deficient NK cells developed normally
and were defective in NKG2D recognition yet retained activity
against MHC-deficient tumor cells and bone marrow grafts.
We chose two models in which mice carrying transoncogenes
develop spontaneous, autochthonous tumors. By using
NKG2D-deficient TRAMP mice, a transgenic model of prostate
adenocarcinoma, and NKG2D-deficient Em-myc mice, a trans-
genic model of B cell lymphoma, we demonstrated that
NKG2D plays a critical role in tumor surveillance in vivo.
RESULTS
Generation of NKG2D-Deficient Gene-Targeted Mice
By gene targeting, we replaced six exons of the Klrk1 gene with
a neo cassette in the Bruce-4 embryonic stem cell line derivedImmunity 28, 571–580, April 2008 ª2008 Elsevier Inc. 571
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NKG2D and Tumor Surveillancefrom inbred C57Bl/6 (B6) mice (Figure S1A available online). By
targeting B6 ES cells, we ensured that the mice would have
the well-characterized B6 NK gene complex, which encodes
many key NK receptors, including the marker NK1.1. We gener-
ated an initial colony of mice in which the neo cassette was re-
tained in the gene and subsequently deleted the neo cassette
by crossing the mice to a B6 strain that expresses the Cre re-
combinase in the germline (Figure S1A). The neo-deleted mice
were backcrossed to B6 mice, and Klrk1 heterozygous offspring
lacking the Cre transgene were intercrossed. The experiments
shown compared Klrk1/, Klrk1+/+, and in some cases Klrk1+/
littermates derived from intercrosses of Klrk1+/ mice from the
neo-deleted or neo-in colonies as indicated.
Klrk1/ (NKG2D-deficient) mice were born in the expected
Mendelian ratio (data not shown). The mice exhibited no visible
alterations in major organs or overt pathology. Therefore,
NKG2D plays a dispensable role in embryonic development, de-
spite early data showing broad expression of Rae1 transcripts in
midstage embryos, especially in the central nervous system
(Nomura et al., 1996).
NK cells were present in normal numbers in the spleen, bone
marrow, lymph node, lung, and liver of Klrk1/ mice (Figures
1A and 1B, data not shown) but lacked NKG2D surface expres-
sion (Figure 1C), whereas cells from Klrk1+/ mice showed mod-
estly reduced cell-surface expression of NKG2D compared to
wild-type mice (Figure 1C).
Klrk1/ mice had normal numbers and proportions of CD4+
and CD8+ T cells, TCRgd T cells, NKT cells, and B cells in the
spleen, bone marrow, and lymph nodes (Figure S2, and data
not shown). The frequency of CD8+CD44+ memory T cells in the
spleen was also normal (data not shown). NK subsets defined by
CD11bandCD27werenot substantiallydifferent,whereasvarious
maturation markers including NK1.1, CD11b, DX5, CD122, and
CD43 were expressed normally (Figures 1A and 1B). The mutant
mice had normal or minor differences in the expression of various
stimulatory and inhibitory receptors including NK1.1, 2B4, Ly49D,
Ly49C, Ly49I, Ly49F, KLRG1, Ly49G2, Ly49A, NKp46, CD94, and
NKG2A (FigureS3,Figure1,datanot shown). Together, thesedata
indicate that NKG2Dexpression is dispensable for normal pheno-
typic development of NK cells, B cells, and T cells.
NKG2D Deficiency Results in a Higher Incidence
of Highly Malignant Prostate Adenocarcinomas
We investigated tumor surveillance in vivo by using the well-
studied transgenic adenocarcinoma of the mouse prostate
(TRAMP) model of autochthonous prostate cancer, which
mimics human clinical disease (Kaplan-Lefko et al., 2003). In
these mice, the rat probasin promoter directs the expression of
the SV40 early genes (T and t antigen) to the prostatic epithelium
at puberty. In male TRAMP mice, mild to severe prostate hyper-
plasia develops by 12 weeks of age, and was followed by the
appearance of severe hyperplasia and adenocarcinoma by
18 weeks of age and metastatic disease by 30 weeks of age
(Huss et al., 2001; Kaplan-Lefko et al., 2003). Previous studies
demonstrated heterogeneity of TRAMP tumors,which varieswith
genotype (Degrassi et al., 2007; Gingrich et al., 1999). Aggressive
early-arising carcinomas were large and progressed rapidly to
poorly differentiated (PD) lesions as defined histologically, which
is indicative of poor prognosis in humanprostate cancer patients.572 Immunity 28, 571–580, April 2008 ª2008 Elsevier Inc.A late-arising form exhibited persistent well differentiated (WD)
and moderately differentiated (MD) lesions and progressed
less rapidly to PD lesions (Degrassi et al., 2007). The aggressive
form was generally substantially rarer in B6 TRAMP mice than
in mice of mixed FvB-B6 genotype (Gingrich et al., 1999).
For our studies, B6-Klrk1/ mice (neo cassette deleted) were
crossed with B6-TRAMP mice, and the pups were intercrossed
to generate male Klrk1/ TRAMP mice (n = 43) as well as
wild-type (Klrk1+/+) TRAMP littermates (n = 33) for comparison.
Male mice were monitored after puberty for development of
prostate tumors. Animals were euthanized when they developed
Figure 1. NK Cell Development Is Preserved in NKG2D-Deficient
Mice
(A and B) Analysis of NK subsets in the bonemarrow (BM, n = 3, [A]) and spleen
(n = 3-5, [B]) of NKG2D-deficient Klrk1/ (neo cassette deleted) mice and
Klrk1+/+ littermate controls. The top groups in (A) and (B) represent gated
NK1.1+CD3 cells, whereas the remaining panels represent gated CD3 cells.
The numbers represent mean percentages (±SD) of cells expressing the indi-
cated markers.
(C) Representative NKG2D staining on freshly isolated NK1.1+CD3 splenic
NK cells is shown for Klrk1/ mice with the neo cassette deleted and litter-
mate controls. Isotype control stain is shown as shaded histogram. The
bone marrow analysis was repeated in one additional independent experi-
ment, and the spleen cell analysis was repeated in two additional independent
experiments, with similar results.
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cause all TRAMP mice develop tumors, the question was
whether NKG2D deficiency results in more aggressive adeno-
carcinomas or alters the kinetics of tumorigenesis. Strikingly,
early-arising, massive prostate tumors were rare in the wild-
type mice and three times more frequent in the NKG2D-deficient
littermates. Defined as those that exceeded the mean mass by
more than 2 standard errors of the mean (SEMs) (i.e., > 2.7 g),
the large tumors arose in 12 of the 43 Klrk1/ mice (27.9%)
compared to only 3 of the 33 wild-type mice (9.1%) (p = 0.029
by Fisher’s exact test) (Figure 2A). As a result, the mean weight
of prostate tissue at necropsy in the Klrk1/ cohort significantly
exceeded that ofKlrk1+/+ TRAMPmice (p= 0.0184byMann-Whit-
ney test) (Figure 2B). Prostate carcinomas were not detected in
the nontransgenic Klrk1/ males under survey (data not shown).
Histological examination of some of the tumors that arose in
this analysis demonstrated that all ten of the large tumors that
Figure 2. Increased Incidence of Large, Early Prostate Carcinomas
in Klrk1/ TRAMP Mice
(A) Each square represents the weight of the prostate tissue and age at nec-
ropsy of individual Klrk1+/+ TRAMP (n = 33) (upper panel) or Klrk1/ TRAMP
littermates (n = 43) (lower panel) mice. Large, early tumors (>2 SEM greater
than the mean weight, circled) were more frequent in Klrk1/ mice
(p = 0.029 by Fisher’s exact test).
(B) The average weights of prostate tumors at necropsy is depicted for both
cohorts (p = 0.0184 by Mann-Whitney test).we examined, eight from Klrk1/ mice and two from wild-type
mice, exhibited nearly uniform PD lesions, whereas only a minor-
ity of the late-arising tumors (4/25) exhibited PD lesions, in most
cases multifocally (Table 1, Figure S4, data not shown). WD le-
sions were detected in most of the late-arising tumors (14/25),
whereas more than a quarter of the late-arising tumors from
mice of either genotypewere classified asphylloides-like tumors,
a nonmalignant epithelial-stromal tumor (Tani et al., 2005) (Table
1). In conclusion, the histology data confirm the highly malignant
status of the early-arising tumors. Thus, NKG2D-deficient mice
are three times more susceptible than wild-type littermates to
highly malignant, early-arising prostate adenocarcinoma, dem-
onstrating that NKG2D-mediated immune mechanisms limit the
development of the most aggressive form of prostate cancer in
B6-TRAMP mice.
Consistent with the role of NKG2D in surveillance of prostate
adenocarcinomas, an analysis of dissociated prostate tumors
from a separate cohort of B6-Klrk1+/+ TRAMP mice showed
common, though sporadic, expression of NKG2D ligands on
the cell surface, whereas normal prostate dissociations did not
express ligands (Figures 3A and 3B). Interestingly, however, li-
gand expression was largely restricted to the smaller late-arising
tumors and absent from the large early-arising ones in these
wild-type mice (Figure 3B). The results raise the possibility that
loss of NKG2D ligands by large aggressive TRAMP tumors re-
flectsNKG2D-dependent immunoselectionor editing (Dunnet al.,
2002). Consistent with this possibility, we observed substantially
higher amounts of Rae1 transcripts in large Klrk1/ tumors as
compared to large Klrk1+/+ tumors (mean 2.12 versus 0.14 rela-
tive units, respectively, n = 4 each, p = 0.028) (Figure 3C, left
panel). Furthermore, both of the dissociated large Klrk1/ tu-
mors we examined showed cell-surface expression of Rae1
and MULT1 (Figure 3D) whereas those from Klrk1+/+ mice did
not. These data suggest that NKG2D-dependent immunoselec-
tion (or editing) favors loss of NKG2D ligands on early-arising,
aggressive tumors. The smaller late-arising tumors, in contrast,
expressed similar amounts of transcripts for NKG2D ligands
whether they arose in Klrk1/ or wild-typemice (Figure 3C, right
panel, and data not shown) and displayed the ligands at the cell
surface (Figure 3B and data not shown). Despite expressing
NKG2D ligands, these tumors were apparently refractory to
NKG2D-mediated surveillance, suggesting that they wereTable 1. Histological Analysis of Prostate Tumors from Klrk1+/+ TRAMP and Klrk1/ TRAMP Mice
Tumor Size and Histology
Genotype of TRAMP Mice
Klrk1+/+ (n = 13) Klrk1/ (n = 22) Combined
Large tumorsa 2/13b 8/22 10/35
PD adenocarcinoma 2/2, 100% 8/8, 100% 10/10, 100%
Smaller tumors 11/13 14/22 25/35
PD adenocarcinoma 1/11, 9.1% 3/14, 21.4% 4/25, 16.0%
WD adenocarcinoma 7/11, 63.4% 7/14, 50.0% 14/25, 56.0%
Phylloides (nonmalignant) 3/11, 27.2% 4/14, 28.6% 7/25, 28.0%
aLarge tumors were defined as those exceeding the mean by more than 2 standard errors of the mean (i.e., > 2.7 g).
b The entries represent the number of large or smaller tumors over the total number of tumors of each genotype examined histologically followed by
the percentage of large or smaller tumors that exhibit the indicated histology. Histological classification was based on the maximal histological grade
observed for a given animal. Poorly differentiated (PD) lesions are most aggressive, whereas well differentiated (WD) lesions less aggressive and
Phylloides tumors are nonmalignant.Immunity 28, 571–580, April 2008 ª2008 Elsevier Inc. 573
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Ex Vivo
(A and B) Reduced cell-surface expression of NKG2D ligands on large, early-
arising B6-TRAMP prostate tumors as compared to smaller, late-arising ones.
Freshly dissociated prostate tissue from a representative nontransgenic
Klrk1+/+ B6 mouse (A) and sets of large and smaller tumors isolated from
Klrk1+/+B6-TRAMPmice (B) were compared. Labeled NKG2D tetramers (plain
line) were used to detect all NKG2D ligands, and streptavidin-PE served as
a negative control (shaded histogram). In a few cases, the specificity of stain-
ing was proved by inhibition with unlabeled NKG2D tetramers (dotted line).
(C) Reduced amounts of Rae1 transcripts in large (>2.7 g) Klrk1+/+ TRAMP tu-
mors as compared to largeKlrk1/ TRAMP tumors (p = 0.0286with theMann-
Whitney test) (left panel) or smallerKlrk1+/+ TRAMP tumors (right panel). Values
determined by quantitative reverse transcriptase (RT)-PCR with primers that
detect all Rae1 isoforms were normalized to HPRT transcript amounts, and
these data were normalized to the amount in nontransgenic B6 prostates (av-
erage of five independent B6 mice). Graphs show the mean ± SD of two to six
separate quantitative PCR (qPCR) assays for each sample.
(D) Cell-surface staining of Rae1 and MULT1 (solid line) on two dissociated
large Klrk1/ TRAMP tumors and a large tumor from an Klrk1+/+ TRAMP litter-574 Immunity 28, 571–580, April 2008 ª2008 Elsevier Inc.sequestered from NKG2D-dependent effector mechanisms or
evaded them (Groh et al., 2002; Lee et al., 2004).
Upon necropsy, the Klrk1+/+ and Klrk1/ mice were also
screened for macroscopic metastases in liver, lung, and kidney.
The percentage of mice with such visible metastases was similar
inKlrk1/ andwild-typemice (approximately 21% in each), rais-
ing the possibility that NKG2D functions primarily at an early
stage of tumorigenesis rather than at the stage of metastasis.
NKG2D Deficiency Accelerates the Progression
of Em-Myc-Induced Lymphomas
In order to study the role of NKG2D in the surveillance of lym-
phoid tumorigenesis, we used Em-myc transgenic mice (Adams
et al., 1985), in which constitutive c-myc oncogene expression
in the B cell lineage results in selective formation of B, pre-B,
or mixed pre-B and B lymphomas (Harris et al., 1988; Langdon
et al., 1986). Genetic crosses were used to generate
B6-Klrk1/ Em-myc transgenic mice (n = 24) and B6-Klrk1+/+
Em-myc transgenic littermates (n = 34), which were monitored
twice weekly after birth for palpable tumors and signs of illness
as manifested by lymphadenopathy, tachnypea, and hunched
posture. Only mice showing enlarged lymphoid organs at nec-
ropsy were designated as having lymphomas. Myc-driven lym-
phomas arose significantly earlier in Klrk1/ mice than in
Klrk1+/+ mice, with the median time of onset occurring more
than 7 weeks earlier in the Klrk1/ mice (p = 0.005 with the
log-rank test) (Figure 4A). None of the nontransgenic Klrk1/
or Klrk1+/+ mice developed lymphoma during a comparable
period of monitoring (data not shown).
Light-scatter analysis of spleen and lymph node cell samples
of all the affected mice showed increased frequencies of lym-
phoblasts compared to nontransgenic samples, suggesting the
presence of tumor cells. Tumors arising in both Klrk1+/+ (n = 7)
and Klrk1/ (n = 5) Emmyc transgenic mice expressed B220
but were heterogeneous with respect to the amount of B220
expression and IgM expression, suggesting that B, pre-B, and
mixed pre-B and B cell lymphomas were represented (Figure 4B
and data not shown). We detected no differences in the distribu-
tion of these tumor types when comparing this small sample of
tumors from Klrk1+/+ versus Klrk1/ mice. NKG2D ligands
Rae1 and MULT1 were not expressed on nontransgenic B cells
but were detected at varying amounts on all the tumor samples
(Figure 4B and data not shown). The amounts of both ligands
varied from tumor to tumor in mice of both genotypes, with
MULT1 expression being more common. There was no indica-
tion in this survey that expression of NKG2D ligands was se-
lected against in Klrk1+/+ mice, despite the clear evidence that
NKG2D-mediated surveillance is operative for these lympho-
mas. These data suggest that evasion of NKG2D-mediated
surveillance by Em-myc-induced lymphomas occurs by mecha-
nisms that do not depend on loss of NKG2D ligands.
NKG2D Deficiency Does Not Affect the Incidence
of Carcinogen-Induced Sarcomas
We addressed the role of NKG2D in the well-studied 3-methyl-
cholanthrene (MCA)-induced carcinogenesis model. Klrk1/
mate. Isotype control stains are shown as shaded histograms. Gated CD45-
negative (nonhematopoietic), PI-negative (live) cells were examined.
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mates were injected with two doses of MCA, and fibrosarcomas
arose at the site of subcutaneous carcinogen application after
a latency period. With a dose of 25 mg MCA, fibrosarcoma inci-
dence was identical in Klrk1/ and Klrk1+/+ mice (Figure 5A,
p = 0.69), whereas with 5 mgMCA, the incidence was, if anything,
lower in Klrk1/ mice, though not significantly (Figure 5B,
p = 0.1). Surprisingly, a separate initial analysis of Klrk1/
mice that retained the neo cassette showed an increased
incidence of MCA-induced tumors (data not shown). However,
because the PGK-neo cassette inserted in a locus can pro-
Figure 4. Accelerated Onset of Myc-Driven
Lymphomas in Klrk1/ Mice
(A) Kaplan-Meier representation of tumor progres-
sion among Klrk1/ Em-myc transgenic (n = 24)
and Klrk1+/+ Em-myc transgenic mice (n = 34).
p = 0.005 by the log-rank test.
(B) Ex vivo analysis of lymph node cell suspen-
sions isolated from Klrk1+/+ Em-myc, Klrk1/
Em-myc, and nontransgenic Klrk1+/+ mice, as indi-
cated. Dot plots show B220 and IgM expression
on the blast (high forward scatter) population
from independent mice that were examined after
the onset of illness. The age (weeks) at necropsy
is specified for each mouse, as well as the per-
centage of cells included in the gate. The histo-
grams show pan-Rae1 and MULT1 expression
(solid line) on the gated populations indicated in
each dot plot. The shaded histograms represent
the staining with an isotype control antibody.
foundly repress the expression of neigh-
boring genes (Kim et al., 1992; Pham
et al., 1996; Xu et al., 1996), and many of
the genes near NKG2D encode NK re-
ceptors, the results with neo-in mice are
clearly unreliable compared to results in
mice where the neo cassette is deleted.
Analysis of numerous freshly dissoci-
ated advanced fibrosarcomas from the
neo-in or neo-deleted mice showed
a great deal of heterogeneity in ligand ex-
pression regardless of Klrk1 genotype,
with some tumors expressing ligands at
a very low level or not at all (data not
shown). Hence, there was no evidence
from these studies that NKG2D selected
for loss of NKG2D ligands by tumor cells
in this model. In conclusion, the present
data do not support an important role
for NKG2D in surveillance of MCA-in-
duced sarcomas in vivo.
Klrk1/ NK Cells Are Defective in
NKG2D Function
but Retain Other NK Cell Functions
The deficient tumor surveillance in
Klrk1/ mice could arise if the mutation
resulted in impaired development of NK
cells, an NK cell subset, or NK cell effector function, as opposed
to a selective deficiency in NKG2D function. As expected, sorted
interleukin-2 (IL-2)-activated NK cells from Klrk1/ mice were
devoid of lytic activity against RMA target cells transfected
with the Rae13 NKG2D ligand (Figure 6A). Klrk1+/ NK cells,
which had lower expression of NKG2D than wild-type cells, me-
diated reduced lysis of these target cells. In contrast, Klrk1/
NK cells were only partially impaired in their capacity to lyse tu-
mor cell lines that naturally express NKG2D ligands, such as
YAC-1 and C1498, comparable to the activity of wild-type NK
cells in the presence of NKG2D antibody (Figures 6B and 6C).Immunity 28, 571–580, April 2008 ª2008 Elsevier Inc. 575
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Induced Fibrosarcomas in NKG2D-Defi-
cient Mice and Wild-Type Littermates
Klrk1/ (dashed line) and wild-type littermates
(solid line) (neo cassette deleted) were injected
subcutaneously (s.c.) with 25 mg (A) or 5 mg (B) of
MCA) and monitored for tumor development.
Tumor-bearing mice were defined by the pres-
ence of a mass of at least 7 mm diameter growing
upon two consecutive measurements. These data
were compiled from two independent experi-
ments. p values are based on the log-rank test.These data validate the findings of earlier studies suggesting that
recognition by NKG2D accounts for only part of the activity of NK
cells against YAC-1 and C1498 tumor cells (Jamieson et al.,
2002). Moreover, NKG2D-deficient NK cells showed no defect
in lysis of the MHC class I-low RMA-S cell line, which lacks
NKG2D ligands and is recognized by an unknown stimulatory
NK receptor other than NKG2D (Figure 6D). These data support
the conclusion that the Klrk1 mutation selectively disables rec-
ognition by NKG2D and does not alter functional recognition
by other NK receptors.
We examined the responsiveness ofKlrk1/NK cells to direct
crosslinking of stimulatory receptors other than NKG2D by using
plate-bound antibodies specific for stimulatory receptors.
Crosslinking of NK1.1 or Ly49D resulted in similar interferon-g576 Immunity 28, 571–580, April 2008 ª2008 Elsevier Inc.(IFN-g) production by Klrk1/ and Klrk1+/+ NK cells. Klrk1/
and Klrk1+/+ NK cells also responded similarly to pharmacologi-
cal stimuli provided by phorbol 12-myristate 13-acetate (PMA)
plus ionomycin (Figure 6E). These data provide direct evidence
that the activating functions of stimulatory NK receptors other
than NKG2D are unaffected by the Klrk1 mutation.
As ameasure of NK functions in vivo in NKG2D-deficient mice,
we tested whether NKG2D participates in ‘‘missing self’’ recog-
nition of bone marrow cells in vivo. Irradiated Klrk1+/+ or Klrk1/
B6 mice were challenged with class I-deficient (B2m/), B6
strain bone marrow cells, mixed in the same inoculum with
wild-type bone marrow cells that served as an internal negative
control (Fernandez et al., 2005). Klrk1+/+ and Klrk1/ recipient
mice rejected the class I-deficient bone marrow grafts similarly,Figure 6. NKG2D Deficiency Does Not
Impair NK Cell Functions In Vitro or In Vivo
(A–C) IL-2-activated splenic NK cells (sorted
NK1.1+CD3 cells in [A], unsorted cells in [B] and
[C]) from Klrk1/mice fail to lyse RMA-Rae13 tar-
get cells, and show reduced lysis of YAC-1 and
C1498 target cells. Lysis in the presence of
NKG2D mAb is shown for Klrk1+/+ (open squares)
and Klrk1/ (open circles) effector cells in (A) and
(B). Results represent means ± SD.
(D) Normal lysis of class I-low RMA-S cells by
Klrk1/ IL-2-activated NK cells. Results repre-
sent means ± SD obtained with Klrk1/ mice
(neo cassette retained) and littermate controls.
(E) Splenocytes from Klrk1/ mice (neo cassette
deleted) and littermate controls (n = 5 for each ge-
notype) were stimulated in vitro for 5 hr on plates
coated with NK1.1 mAb (PK136, 40 mg/ml),
Ly49D mAb (SED85, 10 mg/ml), or control mouse
immunoglobin G (IgG) (40 mg/ml) in the presence
of Golgi plug before staining and analysis. In
parallel, NK cells were stimulated with or without
a mixture of PMA and ionomycin. Intracellular
IFN-g was detected by flow cytometry on
gated NK1.1+CD3 cells, except for the anti-
NK1.1-stimulated cells, which were gated on
DX5+CD3 cells. Results represent means ± SD
(n = 5).
(F) In vivo rejection of B2m/ bone marrow cells
by Klrk1/ mice. A mixture of CFSE- (5 mM) la-
beled BM cells from C57Bl/6-Ly5.2 and B2m/
C57Bl/6-Ly5.1 mice was injected i.v. in irradiated
Klrk1+/+ (n = 4), Klrk1/ (n = 6), negative control
C57Bl/6 B2m/ (n = 2), or NK-depleted Klrk1/
(n = 3) recipients. Similar results were obtained in
one additional independent experiment.
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(mAb) prevented rejection by Klrk1/ mice (Figure 6F). As ex-
pected, B2m/ recipient mice (Klrk1+/+) failed to reject class I-
deficient bone marrow grafts (Bix et al., 1991). These data indi-
cate that NKG2D is not required for rejection of class I-deficient,
B6 strain bone marrow grafts, in line with other studies suggest-
ing no role for NKG2D in rejection of B6 bonemarrow grafts by F1
mice (Ogasawara et al., 2005). Thus, the present data demon-
strate that NKG2D deficiency does not globally impair NK cell
functions in vivo.
DISCUSSION
By using Klrk1 gene-targeted mice, we have provided direct ge-
netic evidence for a role of NKG2D in surveillance of primary
prostate adenocarcinoma and B lymphoma. Transgenic models
of spontaneous malignancy, such as those used here, are usu-
ally considered reliable models of human cancer in comparison
to high-dose carcinogen models, which may not accurately
mimic spontaneous human tumors in many respects (Prehn,
1975). The effect on tumor incidence is likely to be a direct effect
of NKG2D deficiency because we found no substantial alter-
ations in development of NK cells or other cells or in NK cell func-
tions other than those mediated by NKG2D.
Although the role of NKG2D in such models of tumorigenesis
has not been previously investigated, it was previously reported
that methylcolanthrene-induced tumors were more frequent
when mice were treated long-term with blocking NKG2D anti-
bodies (Smyth et al., 2005). In our studies of the MCA carcino-
genesis model, however, we failed to observe an increased inci-
dence of MCA-induced sarcomas in Klrk1/ mice from which
the neo cassette was deleted, with both standard and limiting
MCA doses. The basis of the discrepancy is unknown, but one
possibility is that sustained exposure to high doses of NKG2D
antibodies in vivo, like exposure of NK cells to NKG2D ligands
in vivo (Coudert et al., 2005; Oppenheim et al., 2005), causes
generalized NK cell defects that could impair NK cell-mediated
rejection of target cells recognized via distinct NK receptors. Al-
ternatively, long-term antibody treatment, including the pres-
ence of complexes of injected antibodies and host anti-anti-
bodies, could alter the immune response in unpredictable ways.
Previous studies provided evidence for expression of NKG2D
ligands on primary human tumors (Farag et al., 2002; Groh et al.,
1999; Salih et al., 2003), but there was little data on ligand ex-
pression by primarymouse tumors. The data herein include valu-
able evidence that NKG2D ligands are expressed at the surface
of freshly isolated primary tumor cells ex vivo in twomouse tumor
systems. It was interesting that at the time of necropsy, there
was considerable heterogeneity in the amounts and identity
(Rae1 versus MULT1) of ligands expressed by different tumors.
The heterogeneity cannot be attributed mainly to selection by
NKG2D-dependent mechanisms because it was prevalent
among the tumors arising in NKG2D-deficient mice. It appears
likely, therefore, that the signals that regulate ligand expression
are heterogeneous in advanced tumor cells or that ligands are
in some cases spontaneously downregulated or shed from the
surface of advanced tumor cells, as has been reported else-
where for human tumors (Eisele et al., 2006; Holdenrieder
et al., 2006; Kaiser et al., 2007).Despite this heterogeneity of ligand expression in advanced
tumors, it is likely that nascent tumors express ligands in
a more consistent fashion in at least some of the tumor types
we studied. It seems probable that this is true in the case of
early-arising prostate carcinomas and Em-myc lymphomas be-
cause in both models, NKG2D surveillance had a substantial ef-
fect on the incidence or time of onset of palpable tumors, which
would not be expected if many emerging tumors expressed no
ligands or low amounts of ligands.
Early surveillance would be in accord with published evidence
that NKG2D ligands are induced by the DNA-damage response
(Gasser et al., 2005), which is known to be activated at an early
stage in tumorigenesis (Bartkova et al., 2005; Gorgoulis et al.,
2005). Furthermore, it has been shown that oncogene-induced
stress, such as that which occurs as a result of myc overexpres-
sion, activates the DNA-damage-response pathway (Domi-
nguez-Sola et al., 2007; Reimann et al., 2007; Vafa et al.,
2002). Upregulation of NKG2D ligands as a consequence of
these and other relatively early events in tumorigenesis may sen-
sitize emerging tumor cells to elimination by NKG2D-dependent
mechanisms.
Immunoediting, also called immunoselection, is a process
where immune responses select for variant tumor cells that
have lost expression of specific molecules or antigens that are
targeted by immune effector cells (Dunn et al., 2004). Immunoe-
diting is therefore a likely explanation for our finding that early
arising tumors from Klrk1+/+ mice lacked NKG2D ligands,
whereas tumor cells from Klrk1/ mice did not. We lack evi-
dence, however, that the Rae1-negative tumor cells that arise
in Klrk1+/+mice are the progeny of Rae1+ tumor cells. A possible
prediction of the immunoediting hypothesis is that transfer to
wild-type mice of Rae1+ or MULT1+ tumors from Klrk1/ mice
should lead to rejection, whereas transfer of tumors devoid of
Rae1 and MULT1 expression from Klrk1+/+ mice should not.
Such a study is not currently possible, however, because we
have so far been unable to successfully and reproducibly engraft
primary prostate tumors procured from TRAMPmice into synge-
neic hosts (N.R.G., unpublished data).
In contrast to the results with early-arising TRAMP tumors, ex-
pression of NKG2D did not influence NKG2D ligand expression
by late-arising TRAMP tumors or Em-myc lymphomas, at least
at the advanced stages examined. Em-myc lymphomas differed
from late-arising TRAMP tumors, however, in that Em-myc lym-
phomas were subject to NKG2D-dependent immune surveil-
lance, whereas the late-arising prostate carcinomaswere neither
delayed nor less frequent in hosts that expressed NKG2D as
compared to Klrk1/ hosts, suggesting that they were not sub-
ject to NKG2D-dependent immune surveillance.
Taken together, these data suggest that the role of NKG2D-de-
pendent surveillance differs in the three types of tumors studied
here. In the case of early-arising prostate carcinomas in TRAMP
mice, many of the tumors are eliminated, and the few that are not
eliminated evade surveillance by extinguishing expression of
NKG2D ligands. In the case of Em-myc lymphomas, it appears
that the emerging tumors aremostly NKG2D sensitive, but a frac-
tion of tumors escapeNKG2Dsurveillancewithout losingNKG2D
ligands. Several possible evasion mechanisms can be envis-
aged, including shedding of NKG2D ligands from tumor cells or
other mechanisms that inactivate NKG2D+ effector cells (GrohImmunity 28, 571–580, April 2008 ª2008 Elsevier Inc. 577
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properties necessary for these cells to be recognized by NK cells
and T cells; or rapid tumor growth that outpaces elimination by
NKG2D+ cells, and which may ultimately cause local or systemic
desensitization of NKG2D+ cells (Coudert et al., 2005; Oppen-
heimet al., 2005). The final category is representedby late-arising
prostate carcinomas, which appear to be generally refractory to
NKG2D-dependent surveillance. It is possible that this type of tu-
mor is sequestered fromNKG2D-dependent immune responses,
locally activates inhibitory processes or regulatory cells that inac-
tivate NKG2D+ cells (Lee et al., 2004), or expresses NKG2D li-
gands in a delayed fashion compared to the early-arising ones.
The data herein represent genetic evidence for a role of the
NKG2D receptor in tumor surveillance. The findings add to
a growing number of studies with gene-targeted mice that
have re-energized the immune surveillance theory, by showing
roles for specific immune cells or functions in protection from
cancer (Girardi et al., 2001; Shankaran et al., 2001; Smyth
et al., 2000; van den Broek et al., 1996). The present findings
are unique in showing the role of a specific innate immunity re-
ceptor, NKG2D. Considering that NKG2D is expressed by nu-
merous T cell subsets, the relative roles of NKG2D expressed
by NK cells or T cells is an important issue that will be addressed
in the future. Regardless of the outcome, the data suggest that
interventions to enhance the NKG2D axis of immunity and/or
prevent its deregulation may have applications in cancer immu-
notherapy (Diefenbach et al., 2001; Jinushi et al., 2006; Zhang
et al., 2006; Zhou et al., 2006). Conversely, the observation
that different subtypes of prostate tumors vary in their suscepti-
bility to NKG2D-dependent surveillance suggests that such ap-
plications will need to be tailored to specific cancer subtypes.
EXPERIMENTAL PROCEDURES
Mice
All mice were bred at the University of California, Berkeley, in compliance with
institutional guidelines. C57BL/6J (B6, H-2b), B6-Ly5.1 mice (catalog name,
B6-Ly5.2/Cr), and Em-myc transgenic mice [catalog name, C57BL/6J-Tg
(IghMyc)22Bri/J] were purchased from the Jackson Laboratories (Bar Harbor,
ME). B6-B2m/-Ly5.1 mice were derived in our facilities from B6-B2m/
mice (Zijlstra et al., 1990). C57BL/6 mice harboring a CMV-Cre transgene
were generated from a CD1-Cre transgenic strain provided by Dr. A. Nagy
(Samuel Lunenfeld Research Institute, Toronto, Canada) by backcrossing to
B6. C57BL/6 Tg-TRAMP mice were screened for the presence of the trans-
gene by polymerase chain reaction (PCR) as previously described (Greenberg
et al., 1995). C57BL/6 Tg-Em-myc mice were screened for the presence of the
transgene by PCR with the following primers: forward 50-CAGCTGGCGTAAT
AGCGAAGAG-30 reverse 50-CTGTGACTGGTGAGTACTCAACC-30. Mice were
euthanized by CO2 inhalation in accord with the policies of the Office of
Laboratory Animal and Care (OLAC) at the University of California, Berkeley.
Generation of NKG2D-Deficient Mice
Bruce-4 embryonic stem (ES) cells derived fromC57BL/6mice (Lemckert et al.,
1997) were kindly provided byDr. J.D. Sedgwick (Schering-PloughBiopharma,
Palo Alto, CA) and transfected with a targeting vector (pKSTKNeoLoxP)
designed to delete the exons 1b to 6, encoding the cytoplasmic, transmem-
brane domains and partial extracellular domain of NKG2D (Figure S1A). The
vector contained the neo cassette and was flanked by a thymidine kinase
(TK) cassette. Clones resistant to G418 and Gancyclovir were screened by
Southern blotting with a probe flanking the 30 short arm (Figure S1B), and two
positive clones were confirmed by blotting with a 50 probe (which hybridizes
to the long arm) and a neo probe (data not shown). One targeted clone, BB9,
when injected into BALB/c blastocysts, gave rise to viable chimeras that trans-578 Immunity 28, 571–580, April 2008 ª2008 Elsevier Inc.mitted the disrupted Klrk1 allele when crossed with C57BL/6J (B6/J) females.
The Klrk1+/ B6 progeny of the chimeras were crossed again back to B6/J
and then intercrossed to produce mice of all three genotypes. The same
Klrk1+/mice were separately crossed to a B6 transgenic strain that expresses
Cre recombinase in the germline. Cre-transgene+,Klrk1+/ offspring were bred
back toB6/Jmice, andCre-transgene-negative,Klrk1+/offspring that had de-
leted the neo cassette were identified by PCR and Southern blot and interbred
to produce neo-deleted, Cre-transgene-negative mice of all three Klrk1 geno-
types (+/+, +/, and /). NKG2D-deficient mice were screened for the Klrk1
deletion by PCR with the following primers in the same PCR reaction: WT3 50-
CAGAGCAAGCTTCCTGTTTGTCTCA-30; L1 50-CAAGTAGTGTGCATTTCATT
CAG-30; and p3 50-ATTGCTCCCTGTCTCATTGTCTT-30. The amplification
was carried out as follows: 94C for 4 min, 36 cycles for 94C for 50 s, 55C
for 1min 20 s, 72C for 1min, and a final step at 72C for 10min.When resolved
on a 2% agarose gel, the PCR yielded bands of 422 bp for the wild-type allele
and 317 bp for the mutant allele.
Carcinogenesis
Aged-matched males were shaved and injected subcutaneously with 25 mg or
5 mg of MCA (Sigma Chemical, St. Louis, MO) dissolved completely in olive oil
by heating in boiling water. Mice were examined twice weekly for at least 230
days for palpable tumors at the site of injection. Progressively growingmasses
of 7 mm in diameter or larger were scored as tumors.
Tumor Dissociation and Cell Staining
Solid tumors (MCA-induced fibrosarcomas and the prostate tissues of TRAMP
mice) were dissected and minced in CO2-independent medium (GIBCO) con-
taining collagenase D (1 mg/ml, Roche Applied Science, Indianapolis) and
DNase (1 mg/ml, Roche Applied Science). The tissue was incubated for 1 hr
with shaking at 37C before being passed through a strainer. The suspended
cells were washed twice with Dulbecco’s modified Eagle’s medium (DMEM)
10% fetal calf serum (FCS) and part of the single-cell suspension was used
for ex vivo staining. Enlarged spleen and lymph nodes from Em-myc Tg mice
were dissected and dissociated in RPMI 10% FCS medium, and red blood
cells and dead cells were removed by lympholyte treatment (Lympholyte M,
Cederlane laboratories, Ontario, Canada). Surface staining was performed
on freshly isolated tumor cells after a preincubation step with CD16 mAb to
block the Fc receptors. Staining reagents included CD45-PECY5 mAb (eBio-
science), pan Rae1-PE mAb (R&D Systems, Minneapolis, MN), anti-MULT1
(R&D Systems), and a distinct anti-MULT-1, kindly provided by Dr. S. Jonjic
(University of Rijeka, Croatia) that was biotinylated in our lab (used for studies
in Figure 4). NKG2D tetramer-biot-SAPE has been described (Diefenbach
et al., 2000). Flow histograms obtained from solid tumors are shown for live
cells by gating out the cells labeled with propidium iodide (PI).
Bone Marrow Graft Rejection
Donor bone marrow graft rejection assays were performed as previously de-
scribed (Fernandez et al., 2005). In brief, a mixture of 5 3 106 cells each of
CFSE-labeledB6-B2m/-Ly5.1 andB6 (Ly5.2) bonemarrowcellswas injected
intravenously (i.v.) intomice thathadbeen irradiatedearlier in thedaywith9.5Gy
from a 137Cs source. Recipient spleen cells, harvested 3 days later, were ana-
lyzed forCFSE+Ly5.1+ (class I deficient) andCFSE+Ly5.2+ (nonrejectioncontrol
B6 cells) by flow cytometry. Some mice were predepleted of NK cells by intra-
peritoneal (i.p.) injectionofNK1.1antibody (Fernandezet al., 2005).Graft accep-
tance corresponds to the mean (± standard deviation [SD]) ratio of B2m/
(Ly5.1+) to B6 (Ly5.1) cells among CFSE+ recipient spleen cells.
Statistical Analysis
Statistical comparisons were performed with the log-rank test on Kaplan-
Meier curves depicting lymphomas progression, the Fisher’s exact test to
evaluate prostate tumor incidence, and the two-tailed Mann-Whitney test as-
suming unequal variance. p < 0.05 denotes significance.
SUPPLEMENTAL DATA
Additional Experimental Procedures and four figures are available at http://
www.immunity.com/cgi/content/full/28/4/571/DC1/.
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